Abstract Library

#3132 Plasmatic and urinary 5-hydroxyindolacetic acid measurements in patients with midgut neuroendocrine tumors: A GTE study

Introduction: Although 24-hour urinary 5-hydroxyindolacetic acid (24u5HIAA) is a key biomarker in midgut NET, it may be inaccurate and inconvenient.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: de Mestier L

Authors: de Mestier L, Savagner F, Brixi H, Do Cao C, Dominguez S,

Keywords: neuroendocrine tumor, carcinoid syndrome, 5-hydroxyindolacetic acid, biomarker, diagnosis,

#2061 Midgut Carcinoids Presenting as Subacute Intestinal Obstruction. A Case Report of Territory Care Hospital.

Introduction: Midgut carcinoids are well differentiated neuroendocrine tumors possessing secretary properties releasing various peptides. Over the past few decades, there incidence has been increased. Since countries like Pakistan lack the diagnostic facilities, they are often misdiagnosed.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fatima A

Authors: Fatima A, Zaidi S,

Keywords: midgut carcinoid, liver metastasis, misdiagnosis, surgery,

#1331 The Symptoms Experienced by Small Bowel and Pancreatic NET Patients Prior to Diagnosis Do Not Meet the Criteria for a Functional Diarrhoea (IBS-D) Diagnosis

Introduction: Patients with neuroendocrine tumours (NETs) complain of symptoms that may be mistaken for irritable bowel syndrome (IBS). There is no clear data if these symptoms overlap with those of IBS or if differentiating symptoms co-exist.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Basuroy R, Bouvier C, Sissons M, Ramage J, Srirajaskanthan R,

Keywords: IBS, NET, functional diarrhoea,

#121 Serotonin synthesis inhibitors: a novel approach for managing gastrointestinal symptoms in carcinoid syndrome

Introduction: Carcinoid syndrome (CS) occurs when metastatic carcinoid tumors secrete large amounts of serotonin (5-HT) and other bioactive substances into systemic circulation, causing a variety of symptoms, including GI symptoms such as profound diarrhea. Reduction in 5-HT production by the tumor would be expected to improve symptoms in patients with CS.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Brown P

Authors: Brown P, Jackson J, Frazier K, Turnage A, Clark E,

Keywords: carcinoid syndrome, TPH inhibitor, 5-HT, tryptophan hydroxylase, clinical trial, serotonin synthesis, serotonin synthesis inhibitor, LX1032, LX1031, Lexicon, IBS, irritable bowel syndrome, SSI,